^
CANCER:

B Acute Lymphoblastic Leukemia





Show legend
Group by Gene:
Include preclinical:

brexucabtagene autoleucel
CD19-targeted CAR-T immunotherapy
tisagenlecleucel-T
0
CD19-targeted CAR-T immunotherapy
PBCAR0191
AUTO1
CTX110
pCAR-19B
ISIKOK-19
1
Proteasome inhibitor
bortezomib
carfilzomib
2
Topoisomerase II inhibitor, DNA synthesis inhibitor, DNA-directed DNAP inhibitor
cytarabine + etoposide IV + mitoxantrone
3
DNA synthesis inhibitor
clofarabine
4
Tubulin polymerization inhibitor
vincristine liposomal
5
CD38 inhibitor
daratumumab
isatuximab-irfc
6
Bcl2 inhibitor
venetoclax
7
CD20 inhibitor
rituximab
ofatumumab
8
Bcr-abl tyrosine kinase inhibitor
olverembatinib
nilotinib
9
Multi-tyrosine kinase inhibitor
ponatinib
nintedanib
10
Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor
bosutinib
11
CD19 inhibitor
YT-19
12
Proteasome inhibitor, CD20 inhibitor
rituximab + bortezomib
13
PI3Kδ inhibitor
idelalisib
14
JAK1 inhibitor, JAK2 inhibitor
ruxolitinib
15
CD19 inhibitor, CD3 agonist
blinatumomab
16
Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
dasatinib
17
Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, CAR-T immunotherapy, PDGFR β antagonist, EphA2 receptor antagonist
CAR-T immunotherapy + dasatinib
18
CD22-targeted antibody-drug conjugate, DNA replication inhibitor
inotuzumab ozogamicin
19
PDGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor
imatinib
20
T-lymphocyte cell therapy
T-lymphocyte cell therapy
21
Tyrosine kinase inhibitor
Tyrosine kinase inhibitor
22
Chemotherapy
FLAG-IDA
VPD
23
CAR-T immunotherapy
CAR-T immunotherapy
24
CD22-targeted CAR-T immunotherapy, CD19-targeted CAR-T immunotherapy
CD19-targeted CAR-T immunotherapy + CD22-targeted CAR-T immunotherapy
25
Sphingosine kinase inhibitor
Sphingosine kinase inhibitor
26
JAK inhibitor
JAK inhibitor
27
CD70-targeted CAR-T immunotherapy
CD70-targeted CAR-T immunotherapy
28
CD19 inhibitor, CD3 agonist, CD22-targeted antibody-drug conjugate, DNA replication inhibitor
blinatumomab + inotuzumab ozogamicin
29
Topoisomerase II inhibitor, Tubulin polymerization inhibitor, Aspartate-ammonia ligase inhibitor, Asparagine depleter, DNA intercalator
vincristine + daunorubicin + pegaspargase
30
Topoisomerase II inhibitor, Tubulin polymerization inhibitor, Aspartate-ammonia ligase inhibitor, Asparagine depleter
vincristine + mitoxantrone + pegaspargase
31
THF dehydrogenase inhibitor, Alkylating agent, Tubulin polymerization inhibitor, DNA synthesis inhibitor, Dihydrofolic acid reductase inhibitor, DNA-directed DNAP inhibitor, Aspartate-ammonia ligase inhibitor, Asparagine depleter
cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase
32
CD19 inhibitor, CD3 agonist, CD20 inhibitor
rituximab + blinatumomab
33
THF dehydrogenase inhibitor, Topoisomerase II inhibitor, DNA synthesis inhibitor, Dihydrofolic acid reductase inhibitor, DNA cross linking agent, DNA-directed DNAP inhibitor
cytarabine + methotrexate + idarubicin hydrochloride
34
Bifunctional alkylating agent, Topoisomerase II inhibitor, DNA inhibitor
ifosfamide + etoposide oral + mitoxantrone
35
Topoisomerase II inhibitor, Alkylating agent, DNA inhibitor, DNA synthesis inhibitor
cyclophosphamide + etoposide oral + clofarabine
cyclophosphamide + etoposide oral + nelarabine
36
Aspartate-ammonia ligase inhibitor, Asparagine depleter
calaspargase pegol-mknl
37
Tubulin polymerization inhibitor, Tyrosine kinase inhibitor
Tyrosine kinase inhibitor + vincristine
38
Multi-tyrosine kinase inhibitor, Bcl2 inhibitor
venetoclax + ponatinib
39
CD19 inhibitor, CD3 agonist, Multi-tyrosine kinase inhibitor
ponatinib + blinatumomab
40
CD19 inhibitor, Bcr-abl tyrosine kinase inhibitor, CD3 agonist, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
dasatinib + blinatumomab
41
CD19 inhibitor, CD3 agonist, PD1 inhibitor, CTLA4 inhibitor
nivolumab + ipilimumab + blinatumomab
42
CD19 inhibitor, Bcr-abl tyrosine kinase inhibitor, CD3 agonist
blinatumomab + olverembatinib
43
Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor, Bcl2 inhibitor
venetoclax + flumatinib
44
Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor
flumatinib
45
CD19 inhibitor, CD3 agonist, PD1 inhibitor
nivolumab + blinatumomab
46
CD38 inhibitor, Bcl2 inhibitor
venetoclax + daratumumab
47
Topoisomerase II inhibitor, HDAC inhibitor, Proteasome inhibitor
bortezomib + vorinostat + mitoxantrone
48
PI3K inhibitor, mTOR inhibitor
RTB101
49
Bcr-abl tyrosine kinase inhibitor, Bcl2 inhibitor
venetoclax + olverembatinib
50
IL-7R antagonist
OSE-127
51
eIF4G1 inhibitor, Bcr-abl tyrosine kinase inhibitor, NF-κB inhibitor, mTORC1 inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist, AKT inhibitor
dasatinib + SBI-756
52
HSP90 inhibitor, HDAC inhibitor
vorinostat + BMS-722782
53
JAK inhibitor, HDAC inhibitor, SYK inhibitor
vorinostat + ALXN2075
54
JAK2 inhibitor
CHZ868
55
CDK9 inhibitor
PRT2527
56
Menin-MLL inhibitor, MEK inhibitor
selumetinib + SNDX-5613
57
5T4-targeted antibody-drug conjugate, Microtubule inhibitor
PF-06263507
58
HDAC inhibitor
romidepsin
59
SLC1A5-targeted antibody-drug conjugate, DNA replication inhibitor
MEDI7247
60
CD123-targeted antibody-drug conjugate, DNA replication inhibitor
IMGN632
61
HER2 inhibitor
trastuzumab
62
AKT inhibitor, p70S6K inhibitor
CCT128930
63
MCL1 inhibitor, Bcl2 inhibitor
S63845 + S55746
64
mTOR inhibitor
sirolimus
65
AKT inhibitor
MK-2206
66
CD9 inhibitor
KBA1412
67
Alkylating agent
cyclophosphamide
68
SYK inhibitor
GS-9973
69
TTK inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
dasatinib + nilotinib + S81694
70
TTK inhibitor
S81694
71
BET inhibitor
JQ-1
72
JAK inhibitor, SYK inhibitor
ALXN2075
73
RAS inhibitor, Vav3 inhibitor
IODVA1
74
Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist, JNK inhibitor
dasatinib + JNK-IN-8
75
Menin-MLL inhibitor
DS-1594
76
XPO1 inhibitor, Bcl2 inhibitor
venetoclax + selinexor
77
XPO1 inhibitor
selinexor
78
DNA replication inhibitor, CD19-targeted antibody-drug conjugate
SGN-CD19B
79
Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, Bcl2 inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
venetoclax + dasatinib
80
JAK1 inhibitor, JAK2 inhibitor, Bcl2 inhibitor
venetoclax + ruxolitinib
No biomarker
BCR-ABL1 fusion
BCR-ABL1 T315I
BCR-ABL1 E255V
BCR-ABL1 Q252H + BCR-ABL1 V299L
BCR-ABL1 E255K
CD20 positive
CD20 expression
JAK2 fusion
JAK2 F694L
STRBP-JAK2 fusion
EPOR rearrangement
CRLF2 rearrangement + JAK2 fusion
SH2B3 alteration
ABL2 fusion
IL7R mutation
ABL1 fusion
IL7R expression
CD19 positive
CD19 deletion
KMT2A rearrangement
CD22 positive
TP53 mutation
ATF7IP-PDGFRB fusion
TCF3-PBX1 rearrangement
CD22 expression
TCF3-PBX1 fusion
TP53 deletion
FOXP1-ABL1 Fusion
ATF7IP-PDGFRB translocation
Chr t(3;9)(p13;q34) FOXP1/ABL1
MLL-MLLT1 fusion
PAK4 deletion
CDKN2A deletion
PDGFRB fusion
TP53 mutation + IKZF3 mutation
TP53 mutation + IKZF1 mutation
IKZF3 mutation
IKZF1 mutation
PD-1 overexpression
PAX5 fusion
MLL-AFF1 fusion
ABCB1 3435C>T
CD19 positive + CD20 positive
CRLF2 overexpression
CD58 expression
NCOR1-LYN fusion
EBF1-PDGFRB fusion
GOLGA5-JAK2 fusion
INPP5D-ABL1 fusion
TET2 mutation + NRAS mutation
CD19 negative + CD20 negative + CD22 negative
NUP214-ABL1 fusion
IKZF1 deletion
Chr t(4;11)(q21;q23)
MLL translocation
ETV6-ABL1 fusion
P2RY8-CRLF2 fusion
SSBP2-CSF1R fusion
RCSD1-ABL2 fusion
PAX5-JAK2 fusion
IGH-CRLF2 fusion + JAK2 R867Q
JAK1 S646F
IGH-CRLF2 fusion
IGH-CRLF2 fusion + JAK2 GPInsR683
P2RY8-CRLF2 fusion + JAK2 QGinsR683
AKT2 expression
MYB-TYK2 fusion
RNPC3‐JAK2 fusion + Chr t(1;9)(p13;p22)
IL22 overexpression
SNX2-ABL1 fusion
SF3B1 K666N
CD38 expression
STAT5B-BAG1 fusion
GOLGA4-JAK2 fusion
MLL rearrangement
TNFRSF13C expression
HER-2 expression
ZEB2-JAK2 fusion
ATF7IP-JAK2 fusion
MLL rearrangement
NRAS mutation
CD70 expression
KMT2A rearrangement + RAS mutation
TPBG expression
SLC1A5 underexpression
IL3RA expression
KRAS mutation
FOXO1 underexpression
CD9 expression